A number of firms have modified their ratings and price targets on shares of Nuvation Bio (NYSE: NUVB) recently:7/27/2026 – Nuvation Bio had its price target raised by HC Wainwright from $17.00 to $21.00. 7/22/2026 – Nuvation Bio had its “outperform” rating reaffirmed by Royal Bank Of Canada. Get Nuvation Bio Inc alerts:Nuvation Bio is a clinical-stage biotechnology company dedicated to discovering and developing small-molecule therapies for patients with cancer. By centralizing these capabilities, Nuvation Bio aims to accelerate the translation of promising drug candidates from laboratory research to first-in-human studies. See AlsoReceive News & Ratings for Nuvation Bio Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvation Bio Inc and related companies with MarketBeat.com's FREE daily email newsletter.